Clinical Study on the Integration of Traditional Chinese Medicine Virtual Hanging Therapy With Mesenchymal Stem Cells for the Treatment of Crohn's Disease-Associated Anal Fistula.

NCT ID: NCT07113795

Last Updated: 2025-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

EARLY_PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy and safety of TCM virtual hanging therapy combined with mesenchymal stem cellsin the treatment of CD anal fistula. To establish the standard of clinical diagnosis and treatment and thestandard procedure of operation for the treatment of CD anal fistula by virtual hanging therapy combinedwith mesenchymal stem cells.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease With Perianal Fistulas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Association Group

receiving a combination of TCM dummy therapy and mesenchymal stem cell injection therapy

Group Type EXPERIMENTAL

TCM dummy therapy combined with mesenchymal stem cell injection therapy

Intervention Type PROCEDURE

Combines TCM dummy therapy with mesenchymal stem cell injection, integrating traditional local stimulation and modern stem cell regenerative mechanisms.

Dummy Line Therapy Group

treated solely with dummy line therapy

Group Type ACTIVE_COMPARATOR

Dummy Line Therapy Group

Intervention Type PROCEDURE

Utilizes traditional thread-embedding techniques, placing specialized threads at specific sites to effectively drain inflammatory exudates and necrotic materials.

MSC Group

administered only mesenchymal stem cell injection therapy

Group Type ACTIVE_COMPARATOR

MSC Group

Intervention Type PROCEDURE

Administers mesenchymal stem cell injections directly to target areas, leveraging their differentiation and anti-inflammatory properties to enhance tissue repair.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TCM dummy therapy combined with mesenchymal stem cell injection therapy

Combines TCM dummy therapy with mesenchymal stem cell injection, integrating traditional local stimulation and modern stem cell regenerative mechanisms.

Intervention Type PROCEDURE

Dummy Line Therapy Group

Utilizes traditional thread-embedding techniques, placing specialized threads at specific sites to effectively drain inflammatory exudates and necrotic materials.

Intervention Type PROCEDURE

MSC Group

Administers mesenchymal stem cell injections directly to target areas, leveraging their differentiation and anti-inflammatory properties to enhance tissue repair.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Signed informed consent form.

Diagnosis of Crohn's disease (CD) confirmed at least 6 months prior to screening, based on the Chinese Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing).

Crohn's Disease Activity Index (CDAI) score ≤220, indicating inactive or mildly active CD.

Presence of complex anal fistula confirmed by clinical and MRI evaluation.

Age 18-60 years (inclusive), regardless of sex.

Negative serum/urine pregnancy test for women of childbearing potential; all participants must agree to use effective contraception during and for 6 months after the trial.

Good general health status confirmed by medical history and relevant examinations.

Exclusion Criteria

CDAI \>220 or requiring immediate treatment for active CD.

Patients with rectal/anal stenosis or active proctitis (due to procedural limitations).

Presence of abscess \>2 cm unless treated ≥2 weeks prior to the trial.

History of fistula surgery (except drainage or seton placement), concurrent need for perianal surgery unrelated to fistula, or anticipated need for such surgery within 24 weeks post-treatment.

Systemic steroid therapy within 4 weeks prior to screening.

Abnormal laboratory results:

Liver function: Total bilirubin ≥1.5×ULN; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5×ULN.

Renal function: Creatinine clearance \<60 mL/min or serum creatinine ≥1.5×ULN (measured or calculated by Cockcroft-Gault formula).

Current or history of malignancy (including fistula-related carcinoma).

Severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal (excluding CD), endocrine, pulmonary, cardiac, neurologic, psychiatric, or cerebral diseases.

HIV/syphilis antibody positivity, active HCV/HBV infection, or active tuberculosis.

Known allergy to antibiotics or trial-related agents (e.g., penicillin, streptomycin, gentamicin, aminoglycosides, human serum albumin, human platelet lysate, DMEM cell culture medium, or bovine-derived materials).

Intolerance to anesthesia or contraindications to MRI scanning (e.g., pacemaker, hip prosthesis, severe claustrophobia, gadolinium allergy).

Pregnancy, lactation, or refusal to use effective contraception during and for 6 months post-trial.

Major surgery or severe trauma within the past 6 months.

History of alcohol/drug abuse within 6 months prior to enrollment.

Use of investigational drugs within 12 weeks (84 days) prior to screening.

Inability to comply with the study protocol or other conditions deemed unsuitable by investigators.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Anorectal Center of Nanjing Hospital of Traditional Chinese Medicine

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nanjing Hospital of Traditional Chinese Medicine (Affiliated Hospital of Nanjing University of Chinese Medicine)

Nanjing, Jiangsu, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BE2022674

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MSC Intratissular Injection in Crohn Disease Patients
NCT03901235 RECRUITING PHASE1/PHASE2